Publications

Comparison of Structured Versus Abstracted Comorbidities Using Oncology EHR Data from Cancer Patients in the Flatiron Health Network →

Parrinello CM, Seidl-Rathkopf K, Bennette CS, Bourla A, Nussbaum N, Carson K, Abernethy AP

May 2018

Abstract

ISPOR Annual Meeting

Flatiron-authored

Oncology Data Abstraction: Leveraging the Clinical Expertise of Oncology Nurses to Unlock Clinical Insights from Data in Electronic Health Records →

Connolly D, Maignan K, Donegan J, Fessele K

May 2018

Abstract

Academy Health Annual Research Meeting

Flatiron-authored

Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint →

Curtis MD, Griffith S, Tucker M, Taylor M, Capra W, Carrigan G, Holzman B, Torres AZ, You P, Arnieri B, Abernethy AP

May 2018

Manuscript

Health Services Research

Flatiron-authored

Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials →

O’Connor J, Fessele K, Steiner J, Seidl-Rathkopf K, Carson K, Nussbaum N, Yin E, Adelson K, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

May 2018

Manuscript

JAMA Oncology

Flatiron-authored

Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study →

Agarwala V, Khozin S, Singal G, O'Connell C, Kuk D, Li G, Gossai A, Miller V, Abernethy AP

May 2018

Manuscript

Health Affairs

Flatiron-authored

Identification of Resistance Mechanisms to EGFR Treatment in the Real World Using a Clinicogenomic Database →

Singal G, Agarwal A, Kaushik G, O'Connell C, Alpha-Cobb G, Caron T, Bourque D, Guria A, Frank S, Frampton G, Carson K, Abernethy AP, Miller V

April 2018

Abstract

American Association for Cancer Research Annual Meeting

Flatiron-authored

An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer →

Liede A, Wade S, Lethen J, Hernandez RK, Warner D, Abernethy AP, Finelli A

February 2018

Manuscript

Clinical Therapeutics

Flatiron-authored

Use of Cancer Immunotherapies in the Real-World in the Setting of Microsatellite Instability →

Agarwala V, Gossai A, Singal G, O'Connell C, Li G, Kao K, Bourque D, Feuchtbaum D, Nunnally A, Frampton G, Ali S, Abernethy AP, Kramarz S, Trabucco SE

January 2018

Abstract

ASCO-SITC Clinical Immuno-Oncology Symposium

Flatiron-authored

Real World Treatment Patterns of First-line Combination Therapies Among BRAF+ Metastatic Melanoma Patients →

Ghate S, Tang J, Li Z, Nakasato AR

January 2018

Abstract

ASCO-SITC Clinical Immuno-Oncology Symposium

Real World Treatment Patterns of First-line Combination Therapies Among BRAF+ Metastatic Melanoma Patients Stratified by Tumor Burden →

Ghate S, Tang J, Li Z, Nakasato AR

January 2018

Abstract

ASCO-SITC Clinical Immuno-Oncology Symposium

Survival of Chemotherapy (chemo) Refractory Gastric or Gastroesophageal Junction Cancer (GC/GEJC) Patients From Flatiron Health (FH): Matched Clinical Characteristics to ATTRACTION-2 and CHECKMATE-032 →

Janjigian YY, Le DT, Ott PA, Korytowsky B, Le H, Le TK, Zhang Y, Sanchez T, Maglinte G, Laurie M, Patel D, Shangguan T, Chau I

January 2018

Abstract

ASCO Gastrointestinal Cancers Symposium

Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval →

Khozin S, Abernethy AP, Nussbaum N, Zhi J, Curtis MD, Tucker M, Lee S, Light D, Gossai A, Sorg R, Torres AZ, Patel P, Blumenthal G, Pazdur R

January 2018

Manuscript

The Oncologist

Flatiron-authored

Treatment Dynamics of Bone-Targeting Agents Among Men with Bone Metastases from Prostate Cancer in the United States →

Butler A, Cetin K, Hernandez RK, Reams D, Overman R, Kim J, Hirsch B, Abernethy AP, Liede A, Brookhart A

January 2018

Manuscript

Pharmacoepidemiology & Drug Safety

Flatiron-authored

Real-World Characteristics of CLL Patients Receiving Front-Line Therapy, Using the Flatiron Health Database →

Tang B, Szabo E, Zhou J, Wu J, Brander D

December 2017

Abstract

American Society of Hematology Annual Meeting

Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database →

Chari A, Ung A, Abouzaid S, Ni Q, Parikh K, Agarwal A

December 2017

Abstract

American Society of Hematology Annual Meeting

Real-World Outcomes for Maintenance Treatment Sequencing after Receiving Lenalidomide, Bortezomib, and Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Followed By Autologous Stem Cell Transplant (ASCT) →

Fonseca R, Parikh K, Ung B, Ni Q, Abouzaid S, Agarwal A

December 2017

Abstract

American Society of Hematology Annual Meeting

Sequencing Therapy in Chronic Lymphocytic Leukemia (CLL): Treatment Patterns and Associated Outcomes in Community Practice for Patients with Relapsed/Refractory CLL in the United States →

Kapustyan T, Keim H, Meissner B, Nielsen J, Zhang L, Jiang D

December 2017

Abstract

American Society of Hematology Annual Meeting

Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States →

McGrath L, Hernandez RK, Overman R, Reams D, Liede A, Brookhart A

December 2017

Abstract

American Society of Hematology Annual Meeting

Multiple Myeloma Patients and Risk of Skeletal Related Events – Real-World Evidence in US Oncology Clinics →

Bhatta S, Cyprien L, Fonseca R, Hernandez RK, Kim C

December 2017

Abstract

American Society of Hematology Oncology

Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality →

Miksad RA, Abernethy AP

December 2017

Manuscript

Clinical Pharmacology and Therapeutics

Flatiron-authored

Population Characteristics and Utilization Patterns of Patients Treated with Palbociclib Over 2 Years of Post-Approval →

Xu W, Mardekian J, Wang Y, Harnett J, Bell TJ, McRoy L

December 2017

Abstract

San Antonio Breast Cancer Symposium

Treatment Patterns for Young Women with HR+/HER2- Metastatic Breast Cancer in the United States in the Era of CDK 4/6 Inhibitors →

Burstein H, Mayer E, DeMichele A, Harnett J, Mardekian J, McRoy L, Huang Bartlett C, Koehler M, Fahed Rimawi M

December 2017

Abstract

San Antonio Breast Cancer Symposium

Concordance of Real World Progression Free Survival (PFS) on Endocrine Therapy as First Line Treatment for Metastatic Breast Cancer using Electronic Health Record with Proper Quality Control Versus Conventional PFS from a Phase 3 Trial →

Bartlett CH, Mardekian J, Cotter M, Huang X, Zhang Z, Parrinello CM, Abernethy AP, Koehler M

November 2017

Abstract

San Antonio Breast Cancer Symposium

Flatiron-authored

Distribution of PD-L1 Tumor Expression By Assay Type in Patients with Metastatic NSCLC (mNSCLC) →

Velcheti A, Cao X, Liu F, Patwardhan P

October 2017

Abstract

World Conference on Lung Cancer

Utilization and Timing of Foundation Medicine (FMI) Testing in U.S. Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients →

Wang L, Page D, Shewade A, Lambert P, Arnieri B, Capra W, Khorshid M, Mughal T, Gay L, Foser S

October 2017

Abstract

World Conference on Lung Cancer

Real-World Patient Characteristics, Testing and Treatment Patterns of ALK+ NSCLC →

Gubens M, Wong W, Wu N, Chu L, Schulze K, Illei P

October 2017

Abstract

World Conference on Lung Cancer

ALK Testing Trends and Patterns Among Community Practices in the United States →

Illei P, Wong W, Wu N, Chu L, Schulze K, Gubens M

October 2017

Abstract

World Conference on Lung Cancer

Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US →

Li Y, Appius A, Pattipaka T, Feyereislova A, Cassidy A, Ganti A

October 2017

Abstract

World Conference on Lung Cancer

Biomarker Testing Trends and Treatment Patterns in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients in the United States →

Chu L, Corvino F, Yi J, Zikovic M, Wong W

October 2017

Abstract

World Conference on Lung Cancer

Immune Checkpoint Inhibitor (ICPI) Efficacy and Resistance Detected by Comprehensive Genomic Profiling (CGP) in Non-Small Cell Lung Cancer (NSCLC) →

Ross J, Goldberg M, Albacker L, Gay L, Agarwala V, Elvin J, Vergillo J, Ramkissoon S, Severson E, Daniel S, Ali S, Schrock A, Frampton G, Fabrizio D, Miller V, Singal G, Abernethy AP, Stephens P

September 2017

Abstract

ESMO Annual Congress

Flatiron-authored

Analyzing Biomarkers of Cancer Immunotherapy (CIT) Response Using a Real-World Clinico-Genomic Database →

Singal G, Miller P, Agarwala V, Li G, Gossai A, Albacker L, Goldberg M, He J, Frank S, Bourque D, Ivanov V, Fabrizio D, Caron T, Parker A, Guria A, Miller V, Elvin J, Ross J, Abernethy AP, Stephens P

September 2017

Abstract

ESMO Annual Congress

Flatiron-authored

Treatment Patterns and Clinical Outcomes in Patients with Metastatic Pancreatic Cancer Treated with First-Line Nab-Paclitaxel Plus Gemcitabine: Analysis of US Electronic Health Records from the Flatiron Health Database →

Elizabeth D, Li J, Jirau-licca G, Ondovik M, Nifenecker M, Fish S, Liu H, Huang J, Swern A, Louis C

September 2017

Abstract

ESMO Annual Congress

Treatment and Outcomes of Patients with Advanced Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma in the United States →

Barzi A, Hess L, Zhu Y, Liepa A, Fang Y, Kuder C, Beyrer J, Chao J

September 2017

Abstract

ESMO Annual Congress

Use of Electronic Health Record Data for Quality Reporting →

Abernethy AP, Gippetti J, Parulkar R, Revol C

August 2017

Manuscript

Journal of Oncology Practice

Flatiron-authored

Real-World First-Line Treatment and Overall Survival in Non-Small Cell Lung Cancer Without Known EGFR Mutations or ALK Rearrangements in US Community Oncology Setting →

Abernethy AP, Arunachalam A, Burke T, McKay C, Cao X, Sorg R, Carbone D

June 2017

Manuscript

PLoS One

Flatiron-authored

Evidence of Low Incidence of Myelodysplastic Syndrome (MDS) in Patients Exposed to Bendamustine Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) →

Burke J, Bibeau K, Kahl B, Carson K, Zelentz A, Brander D, Maddocks K, Gerecitano J, Pathak A, Cheson B

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Implementation of the IOM 13 Point Care Plan by OCM Practices →

Fargnoli B, Jaffe N, Bauer-Levey N, Cowing K, Schneider J, Parulkar R, Lee D, Harary O, Holleran R, Zhang S, Revol C, Tran D, Shah R, Abernethy AP, Kolodziej M

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Electronic Calculation of Quality Measures in the EMR is Highly Dependent on Data Capture in Structured Fields: The Oncology Care Model (OCM) Quality Reporting Experience →

Hamrick HJ, Revol C, Parulkar R, Lemmers O, Gippetti J, Bauer-Levey N, Lee D, Fugaro A, Kolodziej M, Green R, Abernethy AP

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Rates of PD-L1 Expression Testing in US Community-Based Oncology Practices for Patients with Metastatic Non-Small Cell Lung Cancer Receiving Nivolumab or Pembrolizumab →

Khozin S, Abernethy AP, Nussbaum N, Zhi J, Curtis MD, Tucker M, Lee S, Light D, Blumenthal G, Pazdur R

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Adoption of Immunotherapy into Real World Practice: Insights from the Use of Checkpoint Inhibitors →

O’Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres AZ, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Racial Disparities in the Use of Programmed Death-1 Checkpoint Inhibitors →

O’Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres AZ, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Disparities in Next Generation Sequencing in a Population-Based Community Cohort of Patients with Advanced Non-Small Cell Lung Cancer →

Presley C, Chiang A, Longtine J, Soulos P, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy AP

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Development and Validation of a Real-World Clinico-Genomic Database →

Singal G, Miller P, Agarwala V, He J, Gossai A, Frank S, Bourque D, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Parker A, Guria A, Frampton G, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller V

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

The Application of Electronic Medical Records (Emrs) As a Virtual Comparator Arm in a Lung Cancer Clinical Trial: a Case Study →

Patel K, Ouwens M, Shire N, Khosla S

June 2017

Abstract

ASCO Annual Meeting

Real World Treatment Patterns of First-line Combination Therapies Among Patients with Metastatic Melanoma and BRAF Mutation →

Qiu Y, Li Z, Tang J, Atanasov P, Mahmood S, Grzegorzewski K, Chen L, Chen J

June 2017

Abstract

ASCO Annual Meeting

Characteristics of Advanced NSCLC Patients Receiving Molecular Diagnostic Testing in US Routine Clinical Practice →

Wang L, Shewade A, Lambert P, Arnieri B, Capra W, Khroshid M, Mughal T, Gay L, Page D, Foser S

June 2017

Abstract

ASCO Annual Meeting

Clinical and Demographic Characteristics of Cll Patients Receiving First-line Bendamustine Plus Rituximab Using the Flatiron Health Database →

Tang B, Gabriel S, Pathak A, Brander D, Zhou J

June 2017

Abstract

ASCO Annual Meeting

Real-World Treatment Pattern and Discontinuation of Systemic Combination Therapies in Metastatic Melanoma →

Qiu Y, Li Z, Tang J, Atanasov P, Mahmood S, Grzegorzewski K, Chen L, Chen J

June 2017

Abstract

ASCO Annual Meeting

Retrospective Indirect Comparison of Alectinib Phase II Data vs Ceritinib Real-World Data in ALK+ NSCLC After Progression on Crizotinib →

Davies J, Martinec M, Martina R, Delmar P, Coudert M, Bordogna W, Golding S, Crane G

May 2017

Abstract

European Lung Cancer Conference

Real-World Rates of Chemotherapy Use Near the End of Life (EOL) in Cancer Patients

Agarwala V, Kraut J, Gippetti J, Revol C, Peterson D, Fessele K, Abernethy AP

March 2017

Abstract

NCCN Annual Conference

Flatiron-authored